

Applicant's Docket No. MPI93-006CP1DV1ACN1DV1M

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In application of: Sundelin, Johan, et al.  
Application No.: 10/643,627      Group No.: 1646  
Filed: August 19, 2003      Examiner: Not yet assigned  
For: RECOMBINANT C140 RECEPTOR ITS AGONISTS AND ANTAGONISTS,  
AND NUCLEIC ACIDS ENCODING THE RECEPTOR

RECEIVED  
APR 14 2004  
PATENT  
TECH CENTER 1600/2900

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL OF PREVIOUSLY RECORDED ASSIGNMENT AND  
PREVIOUSLY RECORDED MERGER DOCUMENT

1. Transmitted herewith for this application are:
  - a. Previously recorded Assignment from Johan Sundelin and Robert M. Scarborough to Cor Therapeutics, Inc. in USSN 08/390,301 (4 pages);
  - b. Previously recorded merger document of Cor Therapeutics, Inc. into Millennium Pharmaceuticals, Inc. in USSN 10/127,691 (12 pages); and
  - c. Return receipt postcard.
2. These documents are being provided to evidence ownership of the above-reference application by Millennium Pharmaceuticals, Inc.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10\*

- ☒ with sufficient postage as first class mail.

- ☐ as "Express Mail Post Office to Addressee"  
Mailing Label No.

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Sean Hunziker/Carolyn Willey

(type or print name of person certifying)

Date: April 1, 2004

**\*WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI93-006CP1DV1ACN1DV1M

3. Correspondence Address

Direct all future correspondence to:

Customer Number 30405


OR

Intellectual Property Department  
MILLENNIUM PHARMACEUTICALS, INC.  
40 Landsdowne Street  
Cambridge, MA 02139

April 1, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By



Tracy M. Sioussat

Registration No. 50,609


40 Landsdowne Street

Cambridge, MA 02139

Telephone - 617-374-7679

Facsimile - 617-551-8820

am/qua  
3-14-96



RECEIVED

APR 14 2004




TECH CENTER 1600/2900

**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

MARCH 07, 1996

REID G. ADLER  
MORRISON & FOERSTER  
2000 PENNSYLVANIA AVENUE, N.W.  
SUITE 5500  
WASHINGTON, D.C. 20006-1888



**UNITED STATES PATENT AND TRADEMARK OFFICE  
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT**

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, NORTH TOWER BUILDING, SUITE 10C35, WASHINGTON, D.C. 20231.

RECORDATION DATE: 08/30/1995

REEL/FRAME: 7687/0823  
NUMBER OF PAGES: 3

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

**ASSIGNOR:**

SUNDELIN, JOHAN

DOC DATE: 03/13/1995

**ASSIGNOR:**

SCARBOROUGH, ROBERT M.

DOC DATE: 03/10/1995

**ASSIGNEE:**

COR THERAPEUTICS  
256 E. GRAND AVENUE  
SAN FRANCISCO, CALIFORNIA 94808

SERIAL NUMBER: 08390301  
PATENT NUMBER:

FILING DATE: 01/25/1995  
ISSUE DATE:

TONYA LEE, EXAMINER  
ASSIGNMENT DIVISION  
OFFICE OF PUBLIC RECORDS

DOCKETED

P13725

CCC

11-15-1995

U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office

Dkt No. 2803-0006 20

Assistant Commissioner for

s or copy thereof.

100089875

1. Name of conveying party(ies):

Johan SUNDELIN and Robert M. SCARBOROUGH

2. Name and address of receiving party(ies):

Name: COR Therapeutics

Internal Address:

Street Address: 256 E. Grand Avenue

City: San Francisco State: CA ZIP: 94808

Additional name(s) & address(es) attached? ☐ Yes ☒ NoName(s) of conveying party(ies) attached? ☐ Yes ☒ No

Nature of conveyance:

☒ Assignment☐ Merger☐ Security Agreement☐ Change of Name☐ Other: \_\_\_\_\_Execution Date: March 13, 1995 and March 10, 1995

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: \_\_\_\_\_

A. Patent Application No.(s)

08/390,301

B. Patent No.(s)

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Reid G. Adler  
 MORRISON & FOERSTER  
 2000 Pennsylvania Avenue, N.W.  
 Suite 5500  
 Washington, D.C. 20006-1888

6. Total number of applications and patents involved: 17. Total fee (37 CFR 3.41): \$40.00☐ Enclosed☒ Authorized to be charged to deposit account

8. Deposit account number:

03-1952

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Reid G. Adler

Name of Person Signing  
 Registration No. 30,988

Kate H. Munnally  
Reg # 29,959  
 Signature for

28 August 1995

Date

Total number of pages comprising cover sheet, attachments and document: 3

Mail documents to be recorded with required cover sheet information to:

Assistant Commissioner for Patents

Box Assignments

Washington, D.C. 20231

# ASSIGNMENT

JOINT

THIS ASSIGNMENT, by Johan Sundelin and Robert M. Scarborough (hereinafter referred to as the assignors), residing at Atles Gr. 3, S-24465 Furulund, SWEDEN and 2544 Belmont Canyon Road, Belmont, CALIFORNIA 94002, respectively, witnesseth:

WHEREAS, the said assignors has invented certain new and useful improvements in RECOMBINANT C140 RECEPTOR, ITS AGONISTS AND ANTAGONISTS, AND NUCLEIC ACIDS ENCODING THE RECEPTOR set forth in an application for Letters Patent of the United States, bearing Serial No. 08/390,301 and filed on January 25, 1995; and

WHEREAS, COR Therapeutics, a corporation duly organized under and pursuant to the laws of Delaware, and having its principal place of business at 256 E. Grand Avenue, San Francisco, California 94808 (hereinafter referred to as the assignee) is desirous of acquiring the entire right, title and interest in and to said inventions and said application for Letters Patent of the United States, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon:

NOW THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient considerations, the receipt of which is hereby acknowledged, the said assignors have sold, assigned, transferred and set over, and by these presents do sell, assign, transfer and set over, unto the said assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned inventions, application for Letters Patent, and any and all Letters Patent or Patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all divisions, continuations, and continuations-in-part of said application, or reissues or extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by the said assignee, for its own use and behoof and the use and behoof of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted, as fully and entirely as the same would have been held and enjoyed by the assignors, had this sale and assignment not been made.

AND for the same consideration, the said assignors hereby covenant and agree to and with the said assignee, its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, the said assignors are the sole and lawful owner of the entire right, title and interest in and to the said inventions and the application for Letters Patent above-mentioned, and that the same are unencumbered and that the said assignors have good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, the said assignors hereby covenant and agree to and with the said assignee, its successors, legal representatives and assigns, that the said assignors will, whenever counsel of the said assignee, or the counsel of its successors, legal representatives and assigns, shall advise that any proceeding in connection with said inventions, or said application for Letters Patent, or any proceeding in connection with Letters Patent for said inventions in any country, including interference proceedings, is lawful and desirable, or that any division, continuation or continuation-in-part of any application for Letters Patent or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent for said inventions, without charge to said assignee, its successors, legal representatives and assigns, but at the cost and expense of the said assignee, its successors, legal representatives and assigns.

AND the said assignors hereby request the Commissioner of Patents to issue said Letters Patent of the United States to the said assignee as the assignee of said inventions and the Letters Patent to be issued thereon for the sole use and behoof of the said assignee, its successors, legal representatives and assigns.

Date March 13, 1995 Name of Inventor Johan Sundelin  
Johan Sundelin

Date \_\_\_\_\_ Name of Inventor \_\_\_\_\_  
Robert M. Scarborough

# ASSIGNMENT

JOINT

THIS ASSIGNMENT, by Johan Sundelin and Robert M. Scarborough (hereinafter referred to as the assignors), residing at Atles Gr. 3, S-24465 Furulund, SWEDEN and 2544 Belmont Canyon Road, Belmont.

CALIFORNIA 94002, respectively, witnesseth:

WHEREAS, the said assignors has invented certain new and useful improvements in RECOMBINANT C140 RECEPTOR, ITS AGONISTS AND ANTAGONISTS, AND NUCLEIC ACIDS ENCODING THE RECEPTOR set forth in an application for Letters Patent of the United States, bearing Serial No. 08/390,301 and filed on January 25, 1995; and

WHEREAS, COR Therapeutics, a corporation duly organized under and pursuant to the laws of Delaware, and having its principal place of business at 256 E. Grand Avenue, San Francisco, California 94808 (hereinafter referred to as the assignee) is desirous of acquiring the entire right, title and interest in and to said inventions and said application for Letters Patent of the United States, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon:

NOW THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient considerations, the receipt of which is hereby acknowledged, the said assignors have sold, assigned, transferred and set over, and by these presents do sell, assign, transfer and set over, unto the said assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned inventions, application for Letters Patent, and any and all Letters Patent or Patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all divisions, continuations, and continuations-in-part of said application, or reissues or extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by the said assignee, for its own use and behoof and the use and behoof of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted, as fully and entirely as the same would have been held and enjoyed by the assignors, had this sale and assignment not been made.

AND for the same consideration, the said assignors hereby covenant and agree to and with the said assignee, its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, the said assignors are the sole and lawful owner of the entire right, title and interest in and to the said inventions and the application for Letters Patent above-mentioned, and that the same are unencumbered and that the said assignors have good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, the said assignors hereby covenant and agree to and with the said assignee, its successors, legal representatives and assigns, that the said assignors will, whenever counsel of the said assignee, or the counsel of its successors, legal representatives and assigns, shall advise that any proceeding in connection with said inventions, or said application for Letters Patent, or any proceeding in connection with Letters Patent for said inventions in any country, including interference proceedings, is lawful and desirable, or that any division, continuation or continuation-in-part of any application for Letters Patent or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent for said inventions, without charge to said assignee, its successors, legal representatives and assigns, but at the cost and expense of the said assignee, its successors, legal representatives and assigns.

AND the said assignors hereby request the Commissioner of Patents to issue said Letters Patent of the United States to the said assignee as the assignee of said inventions and the Letters Patent to be issued thereon for the sole use and behoof of the said assignee, its successors, legal representatives and assigns.

Date \_\_\_\_\_ Name of Inventor \_\_\_\_\_

Date 3-10-95 Name of Inventor Johan Sundelin  
Robert M. Scarborough



UNITED STATES  
PATENT AND  
TRADEMARK OFFICE

MST  
PAT8U

AUGUST 13, 2002


PTAS

Chief Information Officer  
Washington, DC 20231  
www.uspto.gov

MORGAN, LEWIS & BOCKIUS LLP  
MICHAEL S. TUSCAN P.H.  
1111 PENNSYLVANIA AVE., NW  
WASHINGTON, D.C. 20004



\*102122836A\*



UNITED STATES PATENT AND TRADEMARK OFFICE  
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 06/10/2002

REEL/FRAME: 012977/0516  
NUMBER OF PAGES: 7

BRIEF: MERGER (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

COR THERAPEUTICS, INC.

DOC DATE: 02/12/2002

ASSIGNEE:

MILLENNIUM PHARMACEUTICALS, INC.  
75 SIDNEY STREET  
CAMBRIDGE, MASSACHUSETTS 02139

SERIAL NUMBER: 07808329 44481-5002-01  
PATENT NUMBER:

FILING DATE: 12/16/1991  
ISSUE DATE:

mst/mst/RJS  
Abandoned

SERIAL NUMBER: 08477133 44481-5002-06  
PATENT NUMBER:

FILING DATE: 06/07/1995  
ISSUE DATE:

mst/mst/RJS  
Abandoned

SERIAL NUMBER: 09362207 44481-5002-14  
PATENT NUMBER:

FILING DATE: 07/28/1999  
ISSUE DATE:

mst/mst/RJS  
Abandoned

SERIAL NUMBER: 09671346 44481-5002-15  
PATENT NUMBER:

FILING DATE: 09/27/2000  
ISSUE DATE:

mst/mst/RJS

AUG 19 2002

MORGAN, LEWIS & BOCKIUS LLP

DOCKETED

By Saw Date 9/1/02

SERIAL NUMBER: 07854109 44481-5004  
PATENT NUMBER:

FILING DATE: 03/20/1992 MST/MST/RJS  
ISSUE DATE:

SERIAL NUMBER: 08475262 44481-5004-02  
PATENT NUMBER:

FILING DATE: 06/07/1995 MST/MST/RJS  
ISSUE DATE:

SERIAL NUMBER: 09621004 44481-5004-04  
PATENT NUMBER:

FILING DATE: 07/20/2000 MST/MST/RJS  
ISSUE DATE:

SERIAL NUMBER: 08390301 44481-5006-01  
PATENT NUMBER:

FILING DATE: 01/25/1995 MST/MST/RK  
ISSUE DATE: Abandoned

SERIAL NUMBER: 08474414 44481-5006-02  
PATENT NUMBER:

FILING DATE: 06/07/1995 MST/MST/RK  
ISSUE DATE: Abandoned

SERIAL NUMBER: 08486673 44481-5006-06  
PATENT NUMBER: 6297026

FILING DATE: 06/07/1995 MST/MST/RK  
ISSUE DATE: 10/02/2001 C/osed

SERIAL NUMBER: 10127691 44481-5006-09  
PATENT NUMBER:

FILING DATE: 04/23/2002 MST/MST/RK  
ISSUE DATE:

SERIAL NUMBER: 09035135 44481-5007-04  
PATENT NUMBER:

FILING DATE: 03/05/1998 MST/ECW/RJS  
ISSUE DATE: Abandoned

SERIAL NUMBER: 09801089 44481-5008-02  
PATENT NUMBER:

FILING DATE: 03/08/2001 MST/MST/RJS  
ISSUE DATE:

SERIAL NUMBER: 09410738 44481-5010-02  
PATENT NUMBER:

FILING DATE: 10/01/1999 MST/MST/RK  
ISSUE DATE: Abandoned

SERIAL NUMBER: 09947922 44481-5010-03  
PATENT NUMBER:

FILING DATE: 09/07/2001 MST/MST/RK  
ISSUE DATE: Abandoned

SERIAL NUMBER: 07801795 44481-5011  
PATENT NUMBER:

FILING DATE: 12/02/1991 MST/MST/RJS  
ISSUE DATE: Abandoned

SERIAL NUMBER: 08253440 44481-5011-01  
PATENT NUMBER:

FILING DATE: 06/07/1994 MST/MST/RJS  
ISSUE DATE: Abandoned

SERIAL NUMBER: 09419076 44481-5017-07  
PATENT NUMBER:

FILING DATE: 10/15/1999 MST/MST/RJS  
ISSUE DATE:

SERIAL NUMBER: 09585410 44481-5017-05  
PATENT NUMBER:

FILING DATE: 06/02/2000 MST/MST/RJS  
ISSUE DATE:

SERIAL NUMBER: 08089455 44481-5018  
PATENT NUMBER:

FILING DATE: 07/09/1993 MST/ECW/RJS  
ISSUE DATE: Abandoned

SERIAL NUMBER: 08884571 44481-5018-03  
PATENT NUMBER:

FILING DATE: 06/27/1997 MST/ECW/RJS  
ISSUE DATE: Abandoned

SERIAL NUMBER: 09560814 44481-5018-04  
PATENT NUMBER:

FILING DATE: 04/28/2000 MST/ECW/RJS  
ISSUE DATE:



SERIAL NUMBER: 09991888	44481-5025-03	FILING DATE: 11/26/2001	MST/MST/RJS
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09473716	44481-5027-01	FILING DATE: 12/29/1999	MST/MST/RK
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09474076	44481-5028-01	FILING DATE: 12/29/1999	MST/MST/RK
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 10071223	44481-5029-02	FILING DATE: 02/11/2002	MST/MST/RK
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 08975653	44481-5039-02	FILING DATE: 11/21/1997	MST/MST/RJS
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09673302	44481-5043	FILING DATE: 03/23/2001	MST/ECW/SEZ
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09775803	44481-5044-01	FILING DATE: 02/05/2001	MST/ECW/SEZ
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09745842	44481-5053	FILING DATE: 12/26/2000	MST/MST/EDL
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 08948672	44481-5012	FILING DATE: 10/10/1997	
PATENT NUMBER: 6262047		ISSUE DATE: 07/17/2001	Transfer to T+T+C
SERIAL NUMBER: 09500231	44481-5015	FILING DATE: 02/08/2000	
PATENT NUMBER:		ISSUE DATE:	Transfer to T+T+C
SERIAL NUMBER: 09664535	44481-5041-991	FILING DATE: 09/18/2000	---IT+T+C
PATENT NUMBER:		ISSUE DATE:	JAL/ECW/ECW ABANDONED
SERIAL NUMBER: 09663420	44481-5061	FILING DATE: 09/15/2000	
PATENT NUMBER:		ISSUE DATE:	Transferred to T+T+C
SERIAL NUMBER: 10126976	44481-5061-02	FILING DATE: 04/22/2002	
PATENT NUMBER:		ISSUE DATE:	Transferred to T+T+C
SERIAL NUMBER: 09226103	44481-5042	FILING DATE: 01/07/1999	
PATENT NUMBER:		ISSUE DATE:	Transferred to T+T+C
SERIAL NUMBER: 09501370	44481-5045	FILING DATE: 02/11/2000	
PATENT NUMBER:		ISSUE DATE:	Transferred to T+T+C
SERIAL NUMBER: 09501371	44481-5045-01	FILING DATE: 02/11/2000	
PATENT NUMBER: 6399627		ISSUE DATE: 06/04/2002	Transferred to T+T+C
SERIAL NUMBER: 09576637	44481-5046	FILING DATE: 05/24/2000	
PATENT NUMBER:		ISSUE DATE:	Transferred to T+T+C
SERIAL NUMBER: 09576634	44481-5046-01	FILING DATE: 05/24/2000	
PATENT NUMBER:		ISSUE DATE:	Transferred to T+T+C

SERIAL NUMBER: 09576638 44481-5047  
PATENT NUMBER:

FILING DATE: 05/24/2000 Transferred  
ISSUE DATE: to T+T+C

SERIAL NUMBER: 09577131 44481-5047-01  
PATENT NUMBER:

FILING DATE: 05/24/2000 Transferred  
ISSUE DATE: to T+T+C

SERIAL NUMBER: 09576635 44481-5048  
PATENT NUMBER:

FILING DATE: 05/20/2000 Transferred  
ISSUE DATE: to T+T+C

SERIAL NUMBER: 09576636 44481-5048-01  
PATENT NUMBER:

FILING DATE: 05/24/2000 Transferred  
ISSUE DATE: to T+T+C

SERIAL NUMBER: 09576633 44481-5049  
PATENT NUMBER:

FILING DATE: 05/24/2000 Transferred  
ISSUE DATE: to T+T+C

SERIAL NUMBER: 09576632 44481-5049-01  
PATENT NUMBER:

FILING DATE: 05/24/2000 Transferred  
ISSUE DATE: to T+T+C

SERIAL NUMBER: 09577154 44481-5049-02  
PATENT NUMBER:

FILING DATE: 05/24/2000 Transferred  
ISSUE DATE: to T+T+C

SERIAL NUMBER: 09636804 44481-5050  
PATENT NUMBER:

FILING DATE: 08/10/2000 Transferred  
ISSUE DATE: to T+T+C

SERIAL NUMBER: 09662807 44481-5051  
PATENT NUMBER:

FILING DATE: 09/15/2000 Transferred  
ISSUE DATE: to T+T+C

SERIAL NUMBER: 09794214 44481-5051-01  
PATENT NUMBER:

FILING DATE: 02/28/2001 Transferred  
ISSUE DATE: to T+T+C

SERIAL NUMBER: 09714532 44481-5052  
PATENT NUMBER:

FILING DATE: 11/17/2000 Transferred to  
ISSUE DATE: T+T+C

SERIAL NUMBER: 09773383 44481-5055  
PATENT NUMBER:

FILING DATE: 02/01/2001 Transferred to  
ISSUE DATE: T+T+C

SERIAL NUMBER: 09773372 44481-5056  
PATENT NUMBER:

FILING DATE: 02/01/2001 Transferred to  
ISSUE DATE: T+T+C

SERIAL NUMBER: 09773373 44481-5057  
PATENT NUMBER:

FILING DATE: 02/01/2001 Transferred to  
ISSUE DATE: T+T+C

SERIAL NUMBER: 09773374 44481-5058  
PATENT NUMBER:

FILING DATE: 02/01/2001 Transferred to  
ISSUE DATE: T+T+C

SERIAL NUMBER: 09773375 44481-5059  
PATENT NUMBER:

FILING DATE: 02/01/2001 Transferred to  
ISSUE DATE: T+T+C

SERIAL NUMBER: 09775812 44481-5060  
PATENT NUMBER:

FILING DATE: 02/05/2001 Transferred to  
ISSUE DATE: T+T+C

SERIAL NUMBER: 09920325 44481-5060-01  
PATENT NUMBER:

FILING DATE: 08/02/2001 Transferred to  
ISSUE DATE: T+T+C

012977/0516 PAGE 5

SERIAL NUMBER: 09816782 44481-5062  
PATENT NUMBER:

FILING DATE: 03/26/2001 Transferred  
ISSUE DATE: TO TTRC

SERIAL NUMBER: 09816771 44481-5063  
PATENT NUMBER:


FILING DATE: 03/26/2001 Transferred to  
ISSUE DATE: TTRC

SERIAL NUMBER: 09816781 44481-5064  
PATENT NUMBER:

FILING DATE: 03/26/2001 Transferred to  
ISSUE DATE: TTRC

TARA WASHINGTON, EXAMINER  
ASSIGNMENT DIVISION  
OFFICE OF PUBLIC RECORDS

FORM PTO-1595  
(Rev. 6-93)



06-14-2002



102122836

RECORDATION FORM COVER SHEET  
PATENTS ONLY

MENT OF COMMERCE  
ent and Trademark Office

Attorney Docket No.: 44481-0021-US

To the Assistant Commissioner for Patents:  
Please record the attached original documents or copy thereof.

ATTN: BOX ASSIGNMENT

1. Name of conveying party(ies):

COR Therapeutics, Inc.

6-10-02

Additional name(s) of conveying party(ies) attached?

Yes ☒ No

3. Nature of conveyance:

☐ Assignment ☒ Merger  
☐ Security Agreement ☐ Change of Name  
Other \_\_\_\_\_

Execution Date(s): February 12, 2002

2. Name and address of receiving party(ies):

Name: Millennium Pharmaceuticals, Inc.

Street Address: 75 Sidney Street

City: Cambridge State: MA

Country: US Zip: 02139

Additional name(s) & address(es) attached?

Yes ☒ No

RECEIVED  
APR 14 2004  
TECH CENTER 1600/2900

4. Application number(s) or patent number(s):

If this document is being filed together with a new application the execution date of the application is:

A. Patent Application No.(s): 07/808,329

B. Patent No.(s)

Additional numbers attached: ☒ Yes ☐ No See attached Schedule B.

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Michael S. Tuscan, Ph.D.  
Internal Address: Customer No. 009629  
Morgan, Lewis & Bockius LLP

Street Address: 1111 Pennsylvania Ave., NW  
City: Washington State: D.C. Zip: 20004

6. Total number of applications and patents involved: 61

7. Total fee (37 C.F.R. §3.41): \$2440.00

☐ Enclosed

☒ Authorized to be charged to deposit account 50-0310

8. Deposit account number: 50-0310

Attach duplicate of page if paying by deposit account

9. Statement and Signature

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Michael S. Tuscan, Ph.D., Reg. No. 43,210

Name of Person Signing

Signature

Date

06/13/2002 DBYRNE 00000040 500310 07808329

01 JUL 2002 2440.00 CH

Total number of pages including cover sheet, attachments and documents: 8

Schedule B, U.S. applications

Application No.	Filing Date	Title	Ref. No.
07/808,329	1991-12-16	Antithrombosis agents	44481-5002-01
08/477,133	1995-06-07	Agents affecting thrombosis and hemostasis	44481-5002-06
09/362,207	1999-07-28	Agents affecting thrombosis and hemostasis	44481-5002-14
09/671,346	2000-09-27	Agents affecting thrombosis and hemostasis	44481-5002-15
07/854,109	1992-03-20	Glycosylation-mediated inhibition of Factor X	44481-5004
08/475,262	1995-06-07	Glycosylation-mediated inhibition of Factor X	44481-5004-02
09/621,004	2000-07-20	Glycosylation-mediated inhibition of Factor X	44481-5004-04
08/390,301	1995-01-25	Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor	44481-5006-01
08/474,414	1995-06-07	Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor	44481-5006-02
08/486,673	1995-06-07	Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor	44481-5006-06
10/127,691	2002-04-23	Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor	44481-5006-09
09/035,135	1998-03-05	Process for production of inhibited forms of activated blood factors	44481-5007-04
09/801,089	2001-03-08	Modulation of integrin-mediated signal transduction	44481-5008-02
09/410,738	1999-10-01	Methods of screening for compounds that interact with human P <sub>2U2</sub> purinergic receptor	44481-5010-02
09/947,922	2001-09-07	Methods of screening for compounds that interact with human P <sub>2U2</sub> purinergic receptor	44481-5010-03
07/801,795	1991-12-02	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor	44481-5017
08/253,440	1994-06-07	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor	44481-5017-01
09/419,076	1999-10-15	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor	44481-5017-04
09/585,410	2000-06-02	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor	44481-5017-05
08/089,455	1993-07-09	Platelet glycoprotein V gene and uses	44481-5018
08/884,571	1997-06-27	Platelet glycoprotein V gene and uses	44481-5018-03
09/560,814	2000-04-28	Platelet glycoprotein V gene and uses	44481-5018-04

Schedule B, U.S. applications

Application No.	Filing Date	Title	Ref. No.
09/991,888	2001-11-26	Identification of Bap-1, a protein that binds to integrin and is Involved in integrin-mediated signal transduction	44481-5025-03
09/473,716	1999-12-29	Polynucleotides encoding a type V adenylyl cyclase	44481-5027-01
09/474,076	1999-12-29	Cloning and characterization of a human adenylyl cyclase	44481-5028-01
10/071,223	2002-02-11	Cloning and characterization of a human adenylyl cyclase	44481-5029-02
08/975,653	1997-11-21	Modulation of interactions between myosin and integrins	44481-5039-01
09/673,302	2001-03-23	Transgenic mammals expressing mutant GP IIIa	44481-5043
09/775,803	2001-02-05	Transgenic animals having a modified glycoprotein V gene	44481-5044
09/745,842	2000-12-26	P <sub>2</sub> Y <sub>12</sub> receptor	44481-5053
08/948,672	1997-10-10	Selective Factor Xa inhibitors	44481-5012-01
09/500,231	2000-02-08	Selective Factor Xa inhibitors	44481-5015-02
09/664,535	2000-09-18	Benzamides and related inhibitors of Factor Xa	44481-5061-99
09/663,420	2000-09-15	Benzamides and related inhibitors of Factor Xa	44481-5061
10/126,976	2002-04-22	Benzamides and related inhibitors of Factor Xa	44481-5061-02
09/226,103	1999-01-07	Platelet ADP receptor inhibitors	44481-5042
09/501,370	2000-02-11	Alkenyl and alkynyl compounds as inhibitors of Factor Xa	44481-5045
09/501,371	2000-02-11	Inhibitors of Factor Xa	44481-5045-01
09/576,637	2000-05-24	Inhibitors of Factor Xa	44481-5046
09/576,634	2000-05-24	Inhibitors of Factor Xa	44481-5046-01
09/576,638	2000-05-24	Inhibitors of Factor Xa	44481-5047
09/577,131	2000-05-24	Inhibitors of Factor Xa	44481-5047-01
09/576,635	2000-05-24	Inhibitors of Factor Xa	44481-5048
09/576,636	2000-05-24	Inhibitors of Factor Xa	44481-5048-01
09/576,633	2000-05-24	Inhibitors of Factor Xa	44481-5049
09/576,632	2000-05-24	Inhibitors of Factor Xa	44481-5049-01
09/577,154	2000-05-24	Inhibitors of Factor Xa	44481-5049-02
09/636,804	2000-08-10	Inhibitors of Factor Xa	44481-5050

Schedule B, U.S. applications

Application No.	Filing Date	Title	Ref. No.
09/662,807	2000-09-15	Inhibitors of Factor Xa	44481-5051
09/794,214	2001-02-28	Inhibitors of Factor Xa	44481-5051-01
09/714,532	2000-11-17	$\beta$ -Amino acid-, aspartic acid- and diaminopropionic -based inhibitors of Factor Xa	44481-5052
09/773,383	2001-02-01	Indole and benzimidazole inhibitors of Factor Xa	44481-5055
09/773,372	2001-02-01	Indalone and benzimidazolone inhibitors of Factor Xa	44481-5056
09/773,373	2001-02-01	3,4-Dihydro-2h-benzo[1,4]oxazine inhibitors of Factor Xa	44481-5057
09/773,374	2001-02-01	2-[1H]-Quinolone and 2-[1H]-quinoxalone inhibitors of Factor Xa	44481-5058
09/773,375	2001-02-01	Bivalent phenylene inhibitors of Factor Xa	44481-5059
09/775,812	2001-02-05	Platelet ADP receptor inhibitors	44481-5060
09/920,325	2001-08-02	Platelet ADP receptor inhibitors	44481-5060-01
09/816,782	2001-03-26	Oxindole inhibitors of Factor Xa	44481-5062
09/816,771	2001-03-26	Isoquinolone inhibitors of Factor Xa	44481-5063
09/816,781	2001-03-26	Bicyclic sulfonyl amino inhibitors of Factor Xa	44481-5064

# Delaware

PAGE 1


*The First State*

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF OWNERSHIP, WHICH MERGES:

"COR THERAPEUTICS, INC.", A DELAWARE CORPORATION,

WITH AND INTO "MILLENNIUM PHARMACEUTICALS, INC." UNDER THE NAME OF "MILLENNIUM PHARMACEUTICALS, INC.", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE THE TWELFTH DAY OF FEBRUARY, A.D. 2002, AT 6 O'CLOCK P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.



*Harriet Smith Windsor*

Harriet Smith Windsor, Secretary of State

2322355 8100M

AUTHENTICATION: 1610075

020093846

DATE: 02-12-02



**CERTIFICATE OF OWNERSHIP AND MERGER**

**MERGING**

**COR THERAPEUTICS, INC.**  
(a Delaware corporation)

**INTO**

**MILLENNIUM PHARMACEUTICALS, INC.**  
(a Delaware corporation)

Millennium Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the "Corporation"), does hereby certify:

**FIRST:** That the Corporation was incorporated on the 13th day of January, 1993, pursuant to the General Corporation Law of the State of Delaware.

**SECOND:** That the Corporation owns all of the outstanding shares of each class of the stock of COR Therapeutics, Inc., a corporation incorporated on the 4th day of February, 1988 pursuant to the General Corporation Law of the State of Delaware.

**THIRD:** That the Board of Directors of the Corporation, by written action in lieu of a meeting dated the 4th day of February, 2002, duly adopted the following resolutions:

**RESOLVED:** That, pursuant to Section 253 of the Delaware General Corporation Law, the Corporation is hereby authorized to merge COR Therapeutics, Inc., a Delaware corporation which is a wholly owned subsidiary of the Corporation, into the Corporation;

**RESOLVED:** That the President and Secretary of the Corporation be, and each of them hereby is, authorized to execute a Certificate of Ownership and Merger with respect to the merger of COR Therapeutics, Inc. into the Corporation, cause the same to be filed with the Secretary of State of the State of Delaware and take all such other actions and to execute all such other instruments and agreements as the officer or officers so acting may deem appropriate to effect such merger;

**RESOLVED:** That the merger of COR Therapeutics, Inc. into the Corporation shall be effective upon the filing of a Certificate of Ownership and Merger with the Secretary of State of the State of Delaware.

IN WITNESS WHEREOF, the Corporation has caused this Certificate to be signed by its authorized officer this 12th day of February, 2002.

MILLENNIUM  
PHARMACEUTICALS, INC.

By: /s/ Mark J. Levin  
Title: President